Guangzhou AERMIYA Biotechnology Co. Ltd. – Trademark Portfolio

Entity Type: 16

Guangzhou AERMIYA Biotechnology Co. Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 11 (Environmental Control) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include REAMIYA. The owner is based in Guangzhou.

610, 6th F, Hongen chuangyiyuan

No. 19, Gaoqiao St., Baiyun Dist.

Guangzhou 510000 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

REAMIYA
REAMIYA
Registered 2022

Trademark Classifications

Guangzhou AERMIYA Biotechnology Co. Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

11
Environmental Control (1 filing)

Apparatus for lighting, heating, steam generating, cooking, refrigerating, drying

Frequently Asked Questions

How many trademarks does Guangzhou AERMIYA Biotechnology Co. Ltd. have?

Guangzhou AERMIYA Biotechnology Co. Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Guangzhou AERMIYA Biotechnology Co. Ltd. file in?

Guangzhou AERMIYA Biotechnology Co. Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 11 (Environmental Control). Class 11 covers apparatus for lighting, heating, steam generating, cooking, refrigerating, drying.

What are Guangzhou AERMIYA Biotechnology Co. Ltd.'s most well-known trademarks?

Guangzhou AERMIYA Biotechnology Co. Ltd.'s registered trademark portfolio includes well-known marks such as REAMIYA. These are among 1 currently registered trademark in the portfolio.

What is Guangzhou AERMIYA Biotechnology Co. Ltd.'s trademark registration success rate?

Guangzhou AERMIYA Biotechnology Co. Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.